N4 Pharma assigns ex AstraZeneca senior research scientist to lead Nuvec, its lead vaccine delivery program.

N4 Pharma assigns ex AstraZeneca senior research scientist to lead Nuvec, its lead vaccine delivery program.

March 8, 2018 Off By Dino Mustafić

N4 Pharma has recruited a former AstraZeneca senior research scientist to lead the Nuvec, its lead vaccine delivery program.

N4 Pharma said that the Directors have been developing a work plan for the its proprietary Nuvec technology, as it waits the imminent beginning of pilot human trials for its reformulation of sildenafil.

Nuvec is a nanosilica system which targets the delivery of therapeutics such as RNA, DNA, vaccines and targeted cancer therapies and is being positioned as a potential alternative delivery system to lipid nanoparticles and lipid nanosomes.

Appointment of head of Nuvec development

N4 Pharma has appointment Andrew Leishman as Head of Nuvec Development. As a former Astra Zeneca’s Senior Research Scientist, N4 Pharma expects him to brings a wealth of research and development expertise to the its lead vaccine delivery program. Leishman has worked on a variety of clinical and pre-clinical assets across respiratory, inflammation and oncology for several pharmaceutical companies, N4 Pharma noted.